{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:10:55Z","timestamp":1773281455363,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2002,1,5]],"date-time":"2002-01-05T00:00:00Z","timestamp":1010188800000},"content-version":"vor","delay-in-days":1345,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[1998,5]]},"abstract":"<jats:sec><jats:label\/><jats:p>Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D (Departments of Dermatology and Ophthalmology, University of Patras, Greece and the Department of Dermatology, Heinrich\u2010Heine University of D\u00fcsseldorf, Germany). Efficacy and safety of systemic recombinant interferon\u2010alpha in Behcet's disease. <jats:italic>J Intern Med<\/jats:italic> 1998; <jats:bold>243<\/jats:bold>: 367\u201372.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the therapeutic efficacy and safety of systemic recombinant interferon \u03b1\u20102a (IFN \u2010\u03b1) in patients with Behcet's disease (BD) and to determine the incidence of episodes in complete responders during the one\u2010year pretreatment period and follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>An open clinical study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Departments of Dermatology and Ophthalmology, University of Patras, Greece and Department of Dermatology, Heinrich\u2010Heine University of D\u00fcsseldorf, Germany.<\/jats:p><\/jats:sec><jats:sec><jats:title>Subjects<\/jats:title><jats:p>Twelve patients (aged 23\u201352 years) with active BD who had previously been unsuccessfully treated with systemic steroids and\/or immunosuppressives.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>IFN\u2010\u03b1 was administered subcutaneously at a dose of 6 \u00d7 10<jats:sup>6<\/jats:sup> IU per day 3 times per week for 2 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Change of area or number of mucocutaneous lesions, grading score for thrombophlebitis and ocular inflammation, haematological and biochemical parameters and number of episodes during the pretreatment period and the follow\u2010up. Evaluation of IFN\u2010\u03b1 side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine patients (75.0%) revealed a complete remission, two (16.6%) a partial remission and one patient (8.3%) showed no response. During the follow\u2010up in five out of the nine complete responders (55.5%) no episodes of BD were seen, whereas, the other four patients (44.5%) had 1\u20132 episodes, as compared to 5\u20138 and 5\u201312 episodes, respectively, during the pretreatment period. An influenza\u2010like syndrome (fever, nausea and myalgias) appeared during the early phase of therapy in all (but one) patients. No patient had to discontinue IFN\u2010\u03b1 because of intolerance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Subcutaneous human recombinant interferon \u03b1\u20102a appears to be an effective and fairly well tolerated therapy for BD.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2796.1998.00159.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T06:06:47Z","timestamp":1047449207000},"page":"367-372","source":"Crossref","is-referenced-by-count":49,"title":["Efficacy and safety of systemic recombinant interferon\u2010alpha in Behcet's disease"],"prefix":"10.1111","volume":"243","author":[{"family":"Georgiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Monastirli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Pasmatzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Gartaganis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Goerz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Tsambaos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,5]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"271","article-title":"Sur en cas d'iritis a hypopyon recidivant.","volume":"168","author":"Adamantiades B","year":"1931","journal-title":"Ann Oculist"},{"key":"e_1_2_6_3_2","first-page":"1152","article-title":"\u00dcber rezidivierende, aphth\u00f6se, durch em Virus verursachte Geschw\u00fcre am Mund, am Auge und an den Genitalien.","volume":"105","author":"Behcet H","year":"1937","journal-title":"Dermatol Wschr"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197505000-00001"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70233-9"},{"key":"e_1_2_6_6_2","first-page":"385","article-title":"Behcet's disease and streptococcal infection.","volume":"30","author":"Namba K","year":"1986","journal-title":"Jpn J Ophthalmol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-34-1-39"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1992.tb01953.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02505221"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1068811"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199142050-00006"},{"key":"e_1_2_6_12_2","first-page":"356","article-title":"Detection of RNA complementary to herpes\u2010simplex virus in mononuclear cells from patients with Behcet's syndrome and recurrent oral ulcers.","volume":"2","author":"Eglin RP","year":"1982","journal-title":"Lancet"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1982.tb00478.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00407749"},{"key":"e_1_2_6_15_2","first-page":"97\u2010100","article-title":"Morbus Behcet und exogenes Interferon. Erfolgreicher Behandlungsversuch mit rekombiniertem \u03b1 A\u2010IFN.","volume":"38","author":"Stadler R","year":"1987","journal-title":"Hautarzt"},{"key":"e_1_2_6_16_2","first-page":"440","article-title":"Morbus Adamantiades\u2010Behcet. Therapeutischer Einsatz von systemischem rekombinantem Interferon \u03b1\u20102a.","volume":"44","author":"Zouboulis Ch","year":"1993","journal-title":"Hautarzt"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(94)70226-8"},{"key":"e_1_2_6_18_2","first-page":"1098","article-title":"Systemic interferon \u03b12b treatment in Behcet's syndrome.","volume":"21","author":"Hamuryudan V","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246374"},{"key":"e_1_2_6_20_2","first-page":"1078","article-title":"Criteria for diagnosis of Behcet's disease.","volume":"335","author":"International Study Group for Behcet's Disease","year":"1990","journal-title":"Lancet"},{"key":"e_1_2_6_21_2","first-page":"58","article-title":"Effect of inline filtration on post\u2010infusion phlebitis.","volume":"2","author":"Maddox RR","year":"1983","journal-title":"Clin Pharm"},{"key":"e_1_2_6_22_2","first-page":"787\u201092","article-title":"Anti\u2010retinal autoimmunity and circulating immune complexes in patients with retinal vasculitis.","volume":"2","author":"Dumonde DC","year":"1982","journal-title":"Lancet"},{"key":"e_1_2_6_23_2","first-page":"258","article-title":"Virus interference. I. The Interferon.","volume":"147","author":"Lsaacs A","journal-title":"Roc R Soc Lond (Biol)"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jama.1991.03470100067035","article-title":". The interferons. Mechanisms of action and clinical applications.","volume":"266","author":"Baron S","year":"1991","journal-title":"JAMA"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(83)90652-6"},{"key":"e_1_2_6_26_2","first-page":"397","article-title":"Discrimination between nonmalignant and malignant cells by combinations by IFNY\u03b3 and IFN\u03b1\u03b2","volume":"3","author":"Fleischmann Wf Jr","year":"1984","journal-title":"J Biol Response Mod"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-4827(85)80034-3","article-title":"Expression of the 2\u20135A system during the cell cycle.","volume":"159","author":"Wells V","journal-title":"Exp Cell Res"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/iai.52.3.828-833.1986","article-title":"Natural and recombinant IFN inhibit tissue culture cell invasion by Salmonella and","volume":"52","author":"Niesel DW","year":"1986","journal-title":"Shigella. Infect Immun"},{"key":"e_1_2_6_29_2","unstructured":"323: 86\u20139."},{"key":"e_1_2_6_30_2","unstructured":"Interferon and Nonviral Pathogens. New York NY: Marcel Dekker Inc. 1988; 237\u201361."},{"key":"e_1_2_6_31_2","unstructured":"Interferon and Nonviral Pathogens. New York NY: Marcel Dekker Inc. 1988; 53\u201372."},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1697103"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1043016"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273949309085025"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360721"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92549-6"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2796.1998.00159.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2796.1998.00159.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2796.1998.00159.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2796.1998.00159.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T01:51:24Z","timestamp":1694397084000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2796.1998.00159.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1998,5]]}},"alternative-id":["10.1046\/j.1365-2796.1998.00159.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2796.1998.00159.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,5]]}}}